Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.47 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.34 |
| ▸ | WDR5 | P61964 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 4/20 | 0.33 |
| ▸ | TYK2 | P29597 | 4/20 | 0.33 |
| ▸ | JAK1 | P23458 | 2/20 | 0.33 |
| ▸ | JAK3 | P52333 | 2/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL690354 | 0.81 | EGFR (0.52) | EGFRERBB3NPC1FGFR4LCK | |
| SCHEMBL12262579 | 0.81 | NPC1 (0.49) | EGFRERBB3NPC1KMT2AMKNK1 | |
| SCHEMBL31247545 | 0.78 | EGFR (0.52) | EGFRERBB3NPC1JAK2TYK2 | |
| SCHEMBL14380631 | 0.75 | ALDH1A1 (0.50) | KMT2AMEN1 | |
| SCHEMBL690511 | 0.75 | EGFR (0.52) | EGFRERBB3NPC1FGFR4KMT2A | |
| SCHEMBL17265777 | 0.73 | EGFR (0.42) | EGFRERBB3NPC1FGFR4LCK | |
| SCHEMBL15533542 | 0.71 | GRM5 (0.49) | EGFRERBB3NPC1JAK2JAK3 | |
| SCHEMBL28936188 | 0.69 | MEN1 (0.50) | EGFRERBB3NPC1LCKKMT2A | |
| SCHEMBL29919717 | 0.69 | MEN1 (0.50) | EGFRERBB3NPC1LCKKMT2A | |
| SCHEMBL1704424 | 0.67 | EGFR (0.66) | EGFRERBB3LCKMKNK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160279127-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. | 2016-09-29 | — | — | US | disclosed |
| US-20150328223-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. | 2015-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160279127-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | EGFR 1981/4885ERBB3 294/4885NPC1 48/4885 |
| US-20150328223-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | EGFR 1981/4885ERBB3 294/4885NPC1 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.